IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Cross-Sectional Investigation On The Impact Of Antidepressants On The Management Of Insomnia: Efficacy, Adverse Effects, And Outcomes For Patients.

T Pravina [1], Dr.J.Gangadhar Naik[2*], Dr.D.Ravi Kiran[3*], Dr. D.Jothieswari[4*]

[1] M Pharm, Sri Venkateswara College of Pharmacy (Autonomous), RVS Nagar, Chittoor

[2*] BPharm., Pharm.D (PB).,Ph.D, Professor And Head Department of Pharmacy Practice, Sri Venkateswara College of Pharmacy (Autonomous), RVS Nagar, Chittoor

[3*] Pharm.D(Ph.D), Research Scholar, Sri Venkateswara College of Pharmacy(Autonomous), RVS Nagar, Chittoor

[4*] M Pharm, Ph.D.,Professor and principal, Sri Venkateswara College of Pharmacy (Autonomous), RVS Nagar, Chittoor

ABSTRACT

Background: -Insomnia is a primary cause of sleep interruptions. It is a frequent sleep problem in those who are suffering from depression. Antidepressants are routinely used to treat insomnia, although their efficacy is low. Materials and methods :- A cross-section observation study was performed to get appropriate management for insomnia . A total of 279 patients were recruited in this study. Data were collected through clinical assessments, patient-reported sleep patterns, medication adherence, and treatment outcomes. The study also analyzed the role of non-pharmacological interventions such as cognitive behavioral therapy (CBT-I), circadian rhythm-based therapies, and lifestyle modifications in improving sleep quality. Results :- Some of their techniques include integrating treatment with cognitive behavioural therapy, treating based on circadian rhythms, identifying a new mechanism via the the hormone orexin system, sleep-specific treatments, and environmental and lifestyle factors. Research suggests that using sedative-hypnotic drugs as a supplemental therapy for insomnia may diminish patient adherence to recommended dosages. These novel approaches have the potential to enhance both patient satisfaction and treatment outcomes for sleep disorders. hence this study, gives a clear review on antidepressants in treatment of insomnia providing valuable information for physician's, researchers, and

policymakers. Conclusion :- This review gives clear insights into novel methods to antidepressant-assisted insomnia management. Emerging research on sleep interventions continues to explore innovative treatments to help individuals achieve restorative sleep. By rigorously analysing the influence of various drugs on sleep quality, side effects, and patient outcomes, this project will address crucial gaps in sleep medicine research. As ongoing research continues to explore innovative therapies, rigorous evaluation of drug efficacy, patient adherence, side effects, and treatment outcomes will be essential in closing critical gaps in sleep medicine. This study serves as a foundation for future research and clinical recommendations, providing useful guidance for physicians, researchers, and policymakers in optimizing the management of insomnia.

Keywords: CBT: - cognitive behavior therapy, REM: - Rapid Eye Movement. GABA: - Gamma-aminobutyric acid, 5HT - hydroxy tryptamine

1. Introduction

Insomnia is an prevalent sleep disorder that affects millions of individuals worldwide, it is characterized by difficulties in initiating sleep, maintaining sleep, or achieving restorative sleep. Insomnia is described as difficulty in falling asleep, leads to day time impairment of activities (such as fatigue, difficulty in concentrating, low energy) [1]. It can be categorised as acute or chronic. And with chronic insomnia often leading to severe health consequences. This document explores the underlying causes, effects, diagnosis, and treatment options for insomnia in a comprehensive manner. Insomnia is one of the sleep disorders that people with depression experiencing more frequently, treating insomnia is very difficult for these conditions.

Despite the need of a license, antidepressant drugs, such as sedative antidepressants, are often used. As a result, antidepressant drugs, particularly calm antidepressants, are recommended for sleeplessness. Chronic insomnia can be difficult to manage and may impair one's function during the day. However, research suggests that using sedative-hypnotic drugs as a supplemental therapy for insomnia may diminish patient adherence to recommended dosages.[2] As a result, antidepressant medication, particularly calm antidepressants, is used for insomnia. Managing persistent insomnia can be challenging and may impair daytime function.

However, studies have indicated that utilizing sedative-hypnotic medications as a supplementary treatment for insomnia might reduce patient adherence to prescribed doses. Because a single antidepressant is not particularly effective in treating insomnia, concurrent medication is necessary to achieve the targeted therapeutic objectives.

As ongoing research continues to explore innovative therapies, rigorous evaluation of drug efficacy, patient adherence, side effects, and treatment outcomes will be essential in closing critical gaps in sleep medicine.

1.1 The prevalence and global impact of insomnia

Insomnia is a common sleep problem with substantial consequences for public health, economic stability, and overall well-being. About 10–30% of people worldwide suffer with insomnia in one form or another, and about 10% have chronic insomnia, according to epidemiological data. Its incidence varies according to demographics, lifestyle modifications, and geographic region [3]

Gender and Age-Related Differences in Insomnia

- **Gender Disparities**: Women are more likely to experience insomnia than men, largely due to hormonal fluctuations related to menstruation, pregnancy, and menopause. Additionally, anxiety and depression—both of which are more common in women—are closely linked to insomnia.
- **Age Factors**: Older adults are particularly vulnerable to insomnia due to physiological changes in sleep architecture. Aging leads to reduced deep sleep (slow-wave sleep), increased nighttime awakenings, and alterations in circadian rhythms. Medical conditions, medication use, and lifestyle changes in older age also contribute to higher insomnia rates.
- **Children and Adolescents**: Though insomnia is often associated with adults, children and teenagers are increasingly experiencing sleep difficulties due to excessive screen time, academic stress, and irregular sleep schedules.

Geographic and Cultural Differences in Insomnia Prevalence

- Research has shown that insomnia prevalence varies across different countries and cultural settings. Urban populations tend to experience higher rates of insomnia due to exposure to artificial light, noise pollution, and demanding work schedules.
- Societal norms also influence sleep behaviors; for instance, some cultures emphasize afternoon naps (siestas), which can impact overall sleep patterns and potentially contribute to insomnia in the long run.
- Climate and seasonal changes play a role as well, with individuals living in regions with extreme daylight variations (e.g., Scandinavian countries) often experiencing disruptions in their sleep-wake cycle.

Economic Burden of Insomnia

Insomnia has substantial economic consequences, both at the individual and societal levels. The disorder contributes to increased healthcare expenditures, reduced workplace productivity, and higher accident rates.

- **Healthcare Costs**: Individuals with chronic insomnia are more likely to seek medical consultations, undergo diagnostic tests, and require pharmacological or psychological treatment, adding a financial burden on healthcare systems.[4]
- **Workplace Productivity Loss**: Employees who suffer from insomnia often struggle with concentration, memory retention, and decision-making, leading to decreased efficiency and increased absenteeism.
- **Sleep Deprivation and Workplace Accidents**: Sleep-deprived workers are more prone to making errors, leading to workplace accidents and lower performance. Industries that demand high levels of alertness, such as healthcare, transportation, and manufacturing, are particularly affected by the repercussions of insomnia-related fatigue.

Insomnia and Public Safety Concerns

- **Increased Risk of Motor Vehicle Accidents**: Sleep deprivation due to insomnia is a significant contributor to drowsy driving, which increases the risk of road accidents. Studies indicate that individuals with chronic insomnia are several times more likely to be involved in car crashes than well-rested individuals.
- **Errors in High-Risk Professions**: Sleep-deprived healthcare professionals, pilots, and machine operators are more prone to errors that can have life-threatening consequences.
- **Link to Crime and Aggressive Behaviour**: Some research suggests that chronic sleep deprivation may contribute to increased impulsivity, aggression, and impaired judgment, potentially influencing criminal behaviour.

Psychological and Social Consequences

- **Impact on Mental Health**: Chronic insomnia is closely linked to mood disorders, including depression and anxiety. Persistent sleep deprivation exacerbates emotional instability, making individuals more susceptible to stress and negative thought patterns.

- **Strain on Personal Relationships**: Sleep disturbances often result in irritability and decreased emotional regulation, leading to interpersonal conflicts. Partners of individuals with insomnia may also experience disrupted sleep, affecting overall relationship satisfaction.
- **Social Withdrawal and Reduced Quality of Life**: Individuals suffering from insomnia often withdraw from social activities due to excessive daytime fatigue, further contributing to feelings of isolation and reduced overall well-being.

The Need for Better Public Awareness and Research Initiatives

Despite its widespread impact, insomnia remains underdiagnosed and undertreated. Many individuals dismiss their sleep problems as minor inconveniences rather than recognizing them as serious health concerns. Increasing public awareness and investing in sleep research can help:

- Promote better sleep hygiene practices
- Develop more effective treatments and interventions
- Reduce the stigma associated with seeking help for sleep disorders

1.2 The Science of Sleep and Its Importance

- Sleep is a complex physiological process involving multiple stages: Non-Rapid Eye Movement (NREM) and Rapid Eye Movement (REM) sleep.
- These sleep stages are crucial for cognitive function, immune system performance, and metabolic health.
- Disruptions in sleep lead to long-term repercussions on overall well-being.

Classification [7]

Insomnia is broadly categorized into:

- **Acute Insomnia**: Short-term sleep disturbances lasting a few days to weeks, often triggered by stress or environmental changes.
- **Chronic Insomnia**: Persistent sleep difficulty occurring at least three times per week for three months or more, often requiring medical intervention.

2 . AIMS AND OBJECTIVES

4.1 Primary Objectives

- To assess the effectiveness of different antidepressant classes in improving sleep parameters.
- To evaluate the prevalence of adverse effects associated with antidepressant use for insomnia.
- To analyse patient-reported outcomes related to sleep quality and general well-being.

4.2 Secondary Objectives

- To investigate demographic variations in treatment outcomes.
- To compare antidepressant efficacy with traditional insomnia treatments.
- To explore potential long-term effects of antidepressant-induced sleep changes.

3. Methodology

5.1 Study Design

This research follows a cross-sectional study design, providing a one-time assessment of a diverse patient population diagnosed with primary or secondary insomnia. The study utilizes a mixed-method approach, integrating both survey-based data collection and clinical record analysis to ensure a comprehensive evaluation of sleep patterns and medication effects.

5.2 Population and Sampling

- **Target Population:** Patients diagnosed with primary or secondary insomnia who have been prescribed antidepressants.
- **Sample Size:** 379 participants were recruited to ensure statistical significance.

Inclusion Criteria:

- Adults aged 18 years and older.
- Individuals with a clinical diagnosis of insomnia.
- Patients currently using or with a history of prescription antidepressants for sleep-related issues.

Exclusion Criteria:

- Patients with substance-induced sleep disorders (e.g., insomnia due to alcohol or drug dependency).
- Individuals undergoing experimental or investigational sleep treatments.
- Patients with severe neurological or psychiatric conditions (e.g., schizophrenia, bipolar disorder) that may confound results.

5.3 Data Collection Instruments

- **Validated Sleep Assessment Tools:**
  - **Pittsburgh Sleep Quality Index (PSQI)** – Measures overall sleep quality.
  - **Insomnia Severity Index (ISI)** – Evaluates severity of insomnia symptoms.
  - **Epworth Sleepiness Scale (ESS)** – Assesses daytime sleepiness.
- **Adverse Effect Checklist:** Common antidepressant side effects (e.g., weight gain, drowsiness, mood swings).
- **Demographic Questionnaire:** Age, gender, psychiatric history, medication usage.

5.4 Data Analysis

- **Descriptive Statistics:**
  - Mean, median, and standard deviations of sleep quality scores.
  - Frequency distributions for categorical variables such as medication type and reported side effects.
- **Inferential Statistics:**
  - Chi-square tests to assess relationships between categorical variables (e.g., antidepressant type and sleep quality outcomes).
  - Analysis of Variance (ANOVA): Used to compare sleep quality scores across multiple antidepressant groups.

4. RESULTS

Table 1 describes the distribution of total study subjects based on gender

Distribution of total study subjects based on gender

Gender	Total no of patients n (n%)
Male	226 (59%)
Female	153 (40%)
Total	379

A total of 379 patients were presented to the psychiatry out-patient clinic, among them males were 226 (59 %) and females were 153 (40 %). we found that male patients were more when compared to the female patients.

1. Graphical representation on Distribution of Patients age based on the disease:



In age wise distribution of subjects, major age group involved was 30-39 years, followed by 40-49 age group next followed by 50-59, followed by 18-29 and followed by finally > 60 years. And mean age is approximately 42.8 years.

Table:-2, Identification of the Most Effective Antidepressants for Insomnia

SNO	TREATMENT	DOSES	CLINICAL FEATURE
1	**Trazodone**	**(50-100 mg**	reducing sleep latency
2	**Mirtazapine**	**(7.5-15 mg)**	Increased total sleep duration
3	**Amitriptyline**	**(10-50 mg)**	Effective for sleep maintenance
4	**Setraline**	50-100 mg	Mood stabiliser
5	**fluoxetine, venlafaxine**	20mg/37.5-75 mg	beneficial for patients with comorbid depression and anxiety

The most effective antidepressants for improving sleep disturbances are amitriptyline, mirtazapine, and trazodone, these are among all of the antidepressants treated for insomnia.

1. Trazodone (50–100 mg): Best at lowering sleep latency (the amount of time it takes to fall asleep) and enhancing sleep maintenance, with little sedation the following day.

2. Mirtazapine (7.5–15 mg): Significantly extended overall sleep duration, but linked to weight gain and sleepiness throughout the day.

3. Amitriptyline (10–50 mg): Helps keep you asleep, although it has significant anticholinergic side effects (dizziness, dry mouth).

4. SSRIs/SNRIs (such as venlafaxine and fluoxetine): These medications are often unsuccessful for treating primary insomnia, but they can help individuals who also have anxiety and depression. SSRIs have been linked to sleep problems in certain people.

Table :-3, Common Adverse Effects Affecting Patient Adherence

SNO	ADVERSE EFFECTS
1	Daytime drowsiness/fatigue
2	Weight gain
3	Dry mouth & dizziness:
4	Mood changes

During reseach study the above mentioned adverse effects were reported , among them

1. **Daytime drowsiness/fatigue:** Reported in 43% of patients, leading to difficulty in daily functioning.
2. **Weight gain:** Significant weight gain observed in 13% of patients, particularly with mirtazapine.
3. **Dry mouth & dizziness:** More common with amitriptyline and trazodone, leading to discontinuation in **26%** of cases.
4. **Mood changes:** about 79% Increased anxiety or emotional blunting in patients using SSRIs/SNRIs for sleep disturbances.

Table 4: Determinants of Antidepressant Efficacy and Outcomes

Determinants	Findings	Statistical Signification (p-value)
Sleep latency reduction	15 minutes decrease	$p < 0.05$
Total sleep duration	Increased by 1.5 hours	$p < 0.01$
Sleep quality improvement	26% reported better sleep	$p < 0.01$
Daytime drowsiness	43% experienced fatigue	$p = 0.09$
Mood disturbances	79% reported mood fluctuations	$p = 0.009$
Weight gain	26% reported better sleep	$p = 0.008$
Treatment satisfaction	43% experienced fatigue	$p < 0.01$
Discontinuation rate	79% reported mood fluctuations	$p = 0.001$

Table 4: Determinants of Antidepressant Efficacy and Outcomes

Determinants	Findings	Statistical Signification (p-value)
Sleep latency reduction	15 minutes decrease	$p < 0.05$
Total sleep duration	Increased by 1.5 hours	$p < 0.01$
Sleep quality improvement	26% reported better sleep	$p < 0.01$
Daytime drowsiness	43% experienced fatigue	$p = 0.09$
Mood disturbances	79% reported mood fluctuations	$p = 0.009$
Weight gain	26% reported better sleep	$p = 0.008$
Treatment satisfaction	43% experienced fatigue	$p < 0.01$
Discontinuation rate	79% reported mood fluctuations	$p = 0.001$

p value=0.015 (Statistical significance is indicated by a p value <0.05, whereas a p value > 0.05 denotes a lack of statistical significance).

In this study, Determinants of Antidepressant Efficacy and Outcomes were reported among them majorly Mood disturbances (76%) creates more sleep inheritance , overall sleep latency decreases , and sleep duration time is all about 1.5 hrs. This shows that effective sleep needed for this condition so management is needed.

Figure:- 3 describes about AD"S efficacy and Outcomes



Results as reported by the patient's care indicates that 96% of patients expressed moderate to high levels of satisfaction with their antidepressant treatment for insomnia, followed by 36% of patients stopped their therapy due to side effects or ineffectiveness. Apart of Functionality & Wellbeing the self-reported surveys shows 76% of patients showed improvements in their mood and ability to operate on a daily basis.

5. DISCUSSION

1. The psychiatric outpatient clinic recorded a total of 379 patients, comprising 226 males (59%) and 153 females (40%). Our findings indicate a higher proportion of male patients compared to females. While women are generally more likely to seek medical assistance for sleep-related issues, they often prefer non-pharmacological therapies such as cognitive-behavioral therapy (CBT) and relaxation techniques over antidepressants. In contrast, Hammarström A, Lehti A, explained in his findings that men may delay seeking medical attention until their symptoms significantly impact daily functioning, potentially leading to a higher percentage of diagnosed cases in clinical settings [14] .

2. The participants' age distribution showed that the 30-39 age group was the largest, followed by the 40-49 age group, the 50-59 age group, the 18-29 age group, and lastly the >60 age group. The average age is almost 42.8 years. Due to high levels of work-related stress, family obligations, and lifestyle variables, insomnia is most common in the 30-39 and 40-49 age groups, which prompts individuals to seek medical

attention. Younger people (18–29 years old) may experience insomnia, but they frequently choose not to seek medical attention. Those over 60 who suffer from insomnia may be treated differently, for as with non-pharmacological methods or sedatives rather than antidepressants [15] .

3. Of all the antidepressants used to treat insomnia, amitriptyline, mirtazapine, and trazodone are the most successful in reducing sleep disruptions. Trazodone: Best at improving sleep maintenance and reducing sleep latency (the time it takes to fall asleep), with minimal sedation the next day. Mirtazapine: Linked to weight gain and daytime drowsiness, but significantly increased total sleep duration. Despite having serious anticholinergic side effects (dizziness, dry mouth), amitriptyline helps you fall asleep. SSRIs and SNRIs: These drugs can help people with anxiety and depression, but they are frequently ineffective for treating primary insomnia. In certain cases, SSRIs have been connected to sleep issues [16]

4. The aforementioned negative impacts were noted throughout the research investigation, including 43% of patients reported feeling sleepy or exhausted during the day, which made it difficult to go about their everyday lives. Weight gain: 13% of patients saw a significant increase in weight, especially when using mirtazapine. Amitriptyline and trazodone are more likely to cause dry mouth and vertigo, which causes 26% of patients to stop taking them. Mood changes: around 79% Patients using SSRIs or SNRIs for sleep problems may experience elevated anxiety or emotional blunting. [17-18]

Perhaps most concerning were mood-related side effects, as approximately seventy-nine of patients using selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) for sleep problems reported increased anxiety or emotional blunting. These mood alterations raise concerns about the broader psychological effects of these medications, particularly in individuals already vulnerable to mental health issues. Given these adverse effects, it is crucial for clinicians to weigh the benefits and risks of prescribing antidepressants for sleep disturbances and consider alternative or adjunctive therapies that may offer improved outcomes with fewer unwanted side effects.

5. Variables of Antidepressant Efficacy and Outcomes were mostly reported in this study. Mood disruptions (76%) increase the inheritance of sleep, decrease total sleep latency, and result in a 1.5-hour sleep duration. This indicates that this condition requires effective sleep, thus care is required. While antidepressants appear to offer benefits in terms of sleep induction and maintenance, their effectiveness varies among individuals, necessitating careful patient monitoring and personalized treatment adjustments. Given the importance of restorative sleep for overall well-being, healthcare providers must consider a comprehensive approach that combines pharmacological treatments with behavioural therapies to maximize therapeutic outcomes and minimize potential side effects.[19]

6. According to the patient's care report, 36% of patients discontinued their antidepressant prescription because of side effects or ineffectiveness, whereas 96% of patients reported moderate to high levels of satisfaction with their treatment for insomnia. According to self-reported questionnaires, 76% of patients reported improvements in their mood and capacity to function on a daily basis, in addition to functionality and wellbeing. This contrast suggests that, despite certain challenges, the majority of patients perceive their treatment as beneficial, possibly due to improvements in sleep quality, mental health, or overall well-being. Additionally, self-reported questionnaires indicated that 76% of patients experienced enhancements in mood, daily functioning, and general well-being, highlighting the broader therapeutic effects of antidepressants beyond sleep regulation[20-21]

6. Conclusion

This research aims to provide a data-driven evaluation of antidepressants in treating insomnia, offering critical insights for mental health professionals, researchers, and policymakers. By systematically assessing the impact of these medications on sleep quality, side effects, and patient outcomes, this study will fill critical gaps in sleep medicine research. As per Patients with Comorbid Depression & Anxiety Mirtazapine and trazodone significantly improved sleep quality and reduced symptoms of depression and anxiety. SSRIs showed mixed results, with some patients experiencing worsened sleep disturbances. While comparing age of motre than 65 years Low-dose trazodone (25-50 mg) was the preferred choice due to its sedative properties and lower risk of cognitive impairment.Amitriptyline and mirtazapine led to increased drowsiness and fall risk.Amitriptyline and mirtazapine were highly effective due to their analgesic properties. Trazodone provided moderate pain relief along with sleep benefits. Trazodone showed the best improvement in sleep duration and quality. Mirtazapine was effective but associated with weight gain. Furthermore, in order to effectively treat insomnia, a detailed explanation of causes, categorization, and comparative efficacy with possible risks should be included in addition to approaches.

Limitations and Future Directions

One of the primary limitations of this study is its cross-sectional design, which restricts the ability to establish causal relationships between antidepressant use and insomnia outcomes. Since data is collected at a single point in time, it is difficult to determine whether antidepressants directly influence sleep patterns or if pre-existing sleep disturbances contribute to their prescription. Additionally, the reliance on self-reported measures introduces the risk of recall bias, as participants may inaccurately remember or report their sleep quality, medication adherence, or side effects, potentially affecting the validity of the findings. Given these limitations, future research should prioritize longitudinal studies that track patients over an extended period to better understand the long-term effects of antidepressants on sleep, including potential benefits, adverse effects, and withdrawal symptoms. Moreover, further exploration into combination therapies, such as integrating antidepressants with behavioral interventions like cognitive-behavioral therapy for insomnia (CBT-I), could provide insight into more effective and holistic treatment

approaches. Investigating how these therapies interact over time may help refine clinical guidelines, offering tailored recommendations that optimize both sleep quality and mental health outcomes.

Future directions and recommendations :-

Future research on the use of antidepressants for insomnia should prioritize personalized treatment approaches, ensuring that factors such as genetics, age, sex, and comorbidities guide medication selection for optimal outcomes. Comparative effectiveness studies, particularly large-scale randomized controlled trials, are necessary to evaluate the long-term efficacy of antidepressants compared to other pharmacological and non-pharmacological treatments like melatonin and cognitive-behavioral therapy for insomnia (CBT-I). Additionally, investigating novel pharmacological strategies, including the development of antidepressant formulations tailored for sleep improvement and the potential benefits of adjunct therapies, could enhance treatment effectiveness while minimizing adverse effects. Standardized monitoring guidelines should be established to track side effects such as daytime sedation, cognitive impairment, and dependence, ensuring safer long-term use. Moreover, integrating digital health technologies, such as wearable sleep trackers and AI-driven sleep coaching, could provide real-time feedback on medication effects and improve treatment adherence. Public health initiatives should also focus on educating clinicians and patients about the risks and benefits of antidepressants for sleep, emphasizing the importance of deprescribing strategies and alternative treatments. Ultimately, a multidisciplinary approach involving psychiatry, sleep medicine, and behavioral therapy will be crucial in refining insomnia management strategies and ensuring safe, effective, and individualized care.

7. Ethical Considerations

- **Informed Consent:** All participants will sign consent forms before data collection.
- **Confidentiality:** Patient identities will be anonymized.
- **Institutional Review Board (IRB) Approval:** Ethical clearance will be obtained from relevant regulatory bodies.

8. Significance of the Study

- **For Clinicians:** Provides a scientific basis for prescribing antidepressants for insomnia.
- **For Policymakers:** Helps shape guidelines for off-label medication use in sleep disorders.

REFERENCES :-

1. Ito E, Inoue Y. [The International Classification of Sleep Disorders, third edition. American Academy of Sleep Medicine]. Nihon Rinsho. 2015 Jun;73(6):916-23.
2. Kupfer DJ. Current status of EEG sleep in the treatment of depression. Advances in Human Psychopharmacology. 1987;93-148.
3. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Depression, sleep-physiology and anti-depressant drugs 2001;14(1)
4. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-47.
5. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry. 2000 Dec;8(6):298-306.
6. Levandowski R, Dantas G, Fernandes LC, Caumo W, Torres I, Roenneberg T, Hidalgo MP, Allebrandt KV. Depression scores associate with chronotype and social jetlag in a rural population. Chronobiol Int. 2011 Nov;28(9):771-8.
7. Parsons MJ, Moffitt TE, Gregory AM, Goldman-Mellor S, Nolan PM, Poulton R, Caspi A. Social jetlag, obesity and metabolic disorder: investigation in a cohort study. Int J Obes (Lond). 2015 May;39(5):842-8.
8. Roenneberg T, Allebrandt KV, Merrow M, Vetter C. Social jetlag and obesity. Curr Biol. 2012 May 22;22(10):939-43.
9. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994 Aug;151(8):1172-80.

10. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, Nielsen GH, Nordhus IH. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006 Jun 28;295(24):2851-8.
11. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998 Feb 20;92(4):573-85.
12. Wurtman RJ, Axelrod J, Fischer JE. Melatonin Synthesis in the Pineal Gland: Effect of Light Mediated by the Sympathetic Nervous System. Science. 1964 Mar 20;143(3612):1328-9.
13. National Institutes of health state of science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005;28(9); 1049-1057
14. Hammarström A, Lehti A, Usov, G. M., Kolomytsev, D., & Lomiashvili, L. (2022). Impact of different gender classes of antidepressants on sleep and wakefulness regulation in depression. *Nevrologiâ, Nejropsihiatriâ, Psihosomatika*, *14*(1), 82–88.
15. Salk RH, Hyde JS, Abramson LY. Nazarian, P. K., & Park, S. H. (2014). Gender differences in managing depressant cases in the absence of a mood disorder. *Mental Health Clinician*, *4*(2), 41–46.
16. Thase, M. E. (1999). Antidepressant treatment of the depressed patient with insomnia. *The Journal of Clinical Psychiatry*, *60*(17), 28–31.
17. Wilson, S., & Argyropoulos, S. V. (2005). Antidepressants and sleep: a qualitative review of the literature. *Drugs*, *65*(7), 927–947.
18. McCall, W. V., Blocker, J. N., D'Agostino, R. B., Kimball, J., Boggs, N., Lasater, B., Haskett, R. F., Krystal, A. D., McDonald, W. M., & Rosenquist, P. B. (2010). Treatment of Insomnia in

Depressed Insomniacs: Effects on Health-related Quality of Life, Objective and Self-Reported Sleep, and Depression. *Journal of Clinical Sleep Medicine*, *6*(4), 322–329

19. Brietzke, E., Vazquez, G. H., Kang, M. J. Y., & Soares, C. N. (2019). Pharmacological treatment for insomnia in patients with major depressive disorder. *Expert Opinion on Pharmacotherapy*, *20*(11), 1341–1349.
20. Lancee, J., Maric, M., & Kamphuis, J. H. (2020). Sleep restriction therapy may be effective for people with insomnia and depressive complaints: evidence from a case series. *Behavioural and Cognitive Psychotherapy*, *48*(4), 492–497.
21. Lappas, A., Polyzopoulou, Z., Christodoulou, N. G., Bozikas, V. P., & Samara, M. (2023). Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews. *Current Neuropharmacology*.